Kaempferol has potential anti‐coronavirus disease 2019 (COVID‐19) targets based on bioinformatics analyses and pharmacological effects on endotoxin‐induced cytokine storm

Abstract

AbstractCOVID‐19 has infected 272 million patients and caused 5.33 million deaths around the world, and it remains the main global threat. Previous studies revealed that Chinese traditional medicine is an effective treatment for COVID‐19 infection. This study aims to reveal the pharmacological effects of kaempferol, which is the active component of Radix Bupleuri and Tripterygii Radix, and potential mechanisms for the treatment of COVID‐19. Here, we employed the bioinformatics methods to filter the anti‐COVID‐19 candidate genes of kaempferol, which mainly enriched in inflammation (TNF, JUN, etc.) and virus infection (AKT1, JNK, etc.). The Transcription levels of AKT1, JNK and JUN were significantly reduced by kaempferol treatment in the LPS‐activated macrophages. In addition, kaempferol reduced the secretion of inflammatory factors by LPS‐stimulated macrophages, inhibited MAPK/NF‐κB signaling and regulated macrophage polarization to M2 type in vitro, and suppressed endotoxin‐induced cytokine storm and improved survival in mice. Molecular docking analysis demonstrated that kaempferol was probable to bind the COVID‐19 protein 5R84 and formatted hydrogen bond with the residues, the free binding energy of which was lower than the original ligand. In summary, our current work indicates that kaempferol has anti‐COVID‐19 potential through the reduction of COVID‐19‐induced body dysfunction and molecule–protein interaction, and bioinformatics results clarify that some of these key target genes might serve as potential molecular markers for detecting COVID‐19.